References
- Tsimberidou A-M, O'Brien S, Khouri I, et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006; 24(15):2343–2351.
- Parikh SA, Rabe KG, Call TG, et al. Diffuse large B‐cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol. 2013;162(6):774–782.
- Lenartova A, Randen U, Børge Johannesen T, et al. Richter syndrome epidemiology in a large population based chronic lymphocytic leukemia cohort from Norway. Cancer Epidemiol. 2019;60:128–133.
- Ben-Dali Y, Hleuhel M, Brieghel C, et al. Richter’s transformation in patients with chronic lymphocytic leukaemia – a nationwide epidemiological study. Leuk Lymphoma. Current issue.
- Rossi D, Cerri M, Capello D, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to richter syndrome. Br J Haematol. 2008;142(2):202–215.
- Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015; 1(1):80–87.
- Ahn IE, Farooqui MZ, Tian X, et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood. 2018;131(21):2357–2366.
- Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukemia progressing after ibrutinib: a multi-centre open-label phase 2 trial. Lancet Oncol. 2018; 19(1):65–75.
- Robertson LE, Pugh W, O'Brien S, et al. Richter's syndrome: a report on 39 patients. J Clin Oncol. 1993;11(10):1985–1989.
- Bruzzi JF, Macapinlac H, Tsimberidou AM, et al. Detection of Richter’s transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med. 2006; 47(8):1267–1273.
- Falchi L, Keating MJ, Marom EM, et al. Correlation between PDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014; 123(18):2783–2790.
- Mauro FR, Chauvie S, Paoloni F, et al. Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. Leukemia. 2015; 29(6):1360–1365.
- Michallet AS, Sesques P, Rabe KG, et al. An18F-FDG-PET maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter’s syndrome. Leuk Lymphoma. 2016;57(6):1474–1477.
- Mato AR, Wierda WG, Davids MS, et al. Analysis of PET-CT to identify Richter’s transformation in 167 patients with disease progression following kinase inhibitor therapy. Blood. 2017;130(Suppl 1):834.
- Wang Y, Rabe KG, Bold MS, et al. The role of 18F-FDG-PET in detecting Richter’s transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. Haematologica. 2020. Advance online publication.
- Reinert CP, Federmann B, Hofmann J, et al. Computed tomography textural analysis for the differentiation of chronic lymphocytic leukemia and diffuse large B cell lymphoma of Richter syndrome. Eur Radiol. 2019;29(12):6911–6921.